The supplying of the product follows approval from the US Food and Drug Administration (FDA) its 505(b)(2) new drug application (NDA).
Lannett president and CEO Arthur Bedrosian said this is their first drug approval using a 505(b)(2) application.
"We have received orders from drug wholesalers, nursing home providers and distributors," Bedrosian said.